GeneDx Holdings Corp reports results for the quarter ended June 30 - Earnings Summary

GeneDx Holdings

03/08/2026 22:55

GeneDx Holdings Corp WGS.OQ reported quarterly adjusted earnings of 1 cent​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 50 cents.  The mean expectation of nine analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -30 cents to -16 cents per share.
Revenue rose 11.4% to $114.44 million from a year ago; analysts expected $111.01 million. 
GeneDx Holdings Corp's reported EPS for the quarter was a loss of 60 cents​.
The company reported a quarterly loss of $17.74 million.
GeneDx Holdings Corp shares had fallen by 5.2% this quarter and lost 49.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1,171.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is also "buy" 
Wall Street's median 12-month price target for GeneDx Holdings Corp is $85.00, about 23.4% above its last closing price of $65.11
This summary was machine generated from LSEG data August 3 at 09:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.19
0.01
Beat
Mar. 31 2026 
-0.01
-0.28
Missed
Dec. 31 2025 
0.11
0.14
Beat
Sep. 30 2025 
0.42
0.49
Beat